Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Wenners, Antonia Sophie ^a   Mehta, Keyur ^b   Loibl, Sibylle ^b   Park, Hyerim ^a   Mueller, Berit ^e   Arnold, Norbert ^a   Hamann, Sigrid ^a   Weimer, Joerg ^a   Ataseven, Beyhan ^c   Darb Esfahani, Silvia ^e   Schem, Christian ^a   Mundhenke, Christoph ^a   Khandan, Fariba ^d   Thomssen, Christoph ^f   Jonat, Walter ^a   Holzhausen, Hans Juergen ^f   von Minckwitz, Gunther ^b   Denkert, Carsten ^e   Bauer, Maret ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b German Breast Group   (Germany)

^c Department of Obstetrics and Gynaecology   (Germany)

^d AGAPLESION MARKUS KRANKENHAUS   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; NAVELBINE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; CYTOPLASM; ENZYME ACTIVITY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR BIOPSY;

ACUTE-PHASE PROTEINS; ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIPOCALINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REMISSION INDUCTION; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84867311375     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045826     Document Type: Article

References (43)

1. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N, (1993) Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268: 10425-10432.
2. Flower DR, (1996) The lipocalin protein family: structure and function. Biochem J 318 (Pt 1):: 1-14.
3. Bratt T, (2000) Lipocalins and cancer. Biochim Biophys Acta 1482: 318-326.
4. Gwira JA, Wei F, Ishibe S, Ueland JM, Barasch J, et al. (2005) Expression of neutrophil gelatinase-associated lipocalin regulates epithelial morphogenesis in vitro. J Biol Chem 280: 7875-7882.
5. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, et al. (2008) Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 108: 389-397.
6. Stoesz SP, Gould MN, (1995) Overexpression of neu-related lipocalin (NRL) in neu-initiated but not ras or chemically initiated rat mammary carcinomas. Oncogene 11: 2233-2241.
7. Kubben FJ, Sier CF, Hawinkels LJ, Tschesche H, van Duijn W, et al. (2007) Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer 43: 1869-1876.
8. Wang HJ, He XJ, Ma YY, Jiang XT, Xia YJ, et al. (2010) Expressions of neutrophil gelatinase-associated lipocalin in gastric cancer: a potential biomarker for prognosis and an ancillary diagnostic test. Anat Rec (Hoboken) 293: 1855-1863.
9. Zhang H, Xu L, Xiao D, Xie J, Zeng H, et al. (2007) Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion. J Clin Pathol 60: 555-561.
10. Barresi V, Ieni A, Bolignano D, Magno C, Buemi M, et al. (2010) Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: correlation with histotype and histological grade. Oncol Rep 24: 305-310.
11. Iannetti A, Pacifico F, Acquaviva R, Lavorgna A, Crescenzi E, et al. (2008) The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc Natl Acad Sci U S A 105: 14058-14063.
12. Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, et al. (2007) Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer 120: 2426-2434.
13. Tong Z, Wu X, Ovcharenko D, Zhu J, Chen CS, et al. (2005) Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J 391: 441-448.
14. Lee HJ, Lee EK, Lee KJ, Hong SW, Yoon Y, et al. (2006) Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int J Cancer 118: 2490-2497.
15. Barresi V, Di Gregorio C, Reggiani-Bonetti L, Ieni A, Ponz-De Leon M, et al. (2011) Neutrophil gelatinase-associated lipocalin: a new prognostic marker in stage I colorectal carcinoma? Hum Pathol 42: 1720-1726.
16. Sun Y, Yokoi K, Li H, Gao J, Hu L, et al. (2011) NGAL expression is elevated in both colorectal adenoma-carcinoma sequence and cancer progression and enhances tumorigenesis in xenograft mouse models. Clin Cancer Res 17: 4331-4340.
17. Stoesz SP, Friedl A, Haag JD, Lindstrom MJ, Clark GM, et al. (1998) Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer 79: 565-572.
18. Portera CC SS, editor(2007) Neoadjuvant chemotherapy: a step closer to individualized therapy. Alexandria VA: ASCO. 51-55 p.
19. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, et al. (2005) 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330: 217.
20. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B, (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr pp. 96-102.
21. Jones RL, Smith IE, (2006) Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol 7: 869-874.
22. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, et al. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685.
23. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, et al. (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24: 2019-2027.
24. Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, et al. (2007) HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 7: 36.
25. Maur M, Guarneri V, Frassoldati A, Conte PF, (2006) Primary systemic therapy in operable breast cancer: clinical data and biological fall-out. Ann Oncol 17 Suppl 5: v158-164.
26. Fernandez-Sanchez M, Gamboa-Dominguez A, Uribe N, Garcia-Ulloa AC, Flores-Estrada D, et al. (2006) Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer. Med Oncol 23: 171-183.
27. Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, et al. (2004) The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 40: 342-351.
28. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, et al. (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685.
29. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, et al. (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23: 7265-7277.
30. Thuerigen O, Schneeweiss A, Toedt G, Warnat P, Hahn M, et al. (2006) Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 24: 1839-1845.
31. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, et al. (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24: 4236-4244.
32. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, et al. (2008) Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 100: 552-562.
33. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, et al. (2008) Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100: 542-551.
34. Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, et al. (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124: 133-140.
35. Harvey JM, Clark GM, Osborne CK, Allred DC, (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481.
36. Friedl A, Stoesz SP, Buckley P, Gould MN, (1999) Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J 31: 433-441.
37. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
38. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
39. Tewari M, Krishnamurthy A, Shukla HS, (2008) Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol 17: 301-311.
40. von Minckwitz G, Muller BM, Loibl S, Budczies J, Hanusch C, et al. (2011) Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 29: 2150-2157.
41. Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, et al. (2009) Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res 11: 205.
42. Bolignano D, Donato V, Lacquaniti A, Fazio MR, Bono C, et al. (2010) Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett 288: 10-16.
43. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, et al. (2005) The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 11: 5390-5395.